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ABSTRACT The aims of the study were to meet the
demand of new tubulin antagonists with fewer side
effects by characterizing the antiangiogenic properties
of the experimental compound spongistatin 1, and to
elucidate nonmitotic mechanisms by which tubulin an-
tagonists inhibit angiogenesis. Although tubulin-inhibit-
ing drugs and their antiangiogenic properties have been
investigated for a long time, surprisingly little is known
about their underlying mechanisms of action. Antian-
giogenic effects of spongistatin 1 were investigated in
endothelial cells in vitro, including functional cell-based
assays, live-cell imaging, and a kinome array, and in the
mouse cornea pocket assay in vivo. Spongistatin 1
inhibited angiogenesis at nanomolar concentrations
(IC50: cytotoxicity>50 nM, proliferation 100 pM, mi-
gration 1.0 nM, tube formation 1.0 nM, chemotaxis 1.0
nM, aortic ring sprouting 500 pM, neovascularization
in vivo 10 g/kg). Further, a kinome array and validat-
ing data showed that spongistatin 1 inhibits the phos-
phorylation activity of protein kinase C (PKC), an
essential kinase in angiogenesis, and its translocation to
the membrane. Thus, we conclude that PKC might be
an important target for the antiangiogenic effects of
tubulin antagonism. In addition, the data from the kinase
array suggest that different tubulin antagonists might have
individual intracellular actions.—Rothmeier, A. S., Isch-
enko, I., Joore, J., Garczarczyk, D., Fu¨rst, R., Bruns, C. J.,
Vollmar, A. M., Zahler, S. Investigation of the marine
compound spongistatin 1 links the inhibition of PKC
translocation to nonmitotic effects of tubulin antagonism
in angiogenesis. FASEB J. 23, 1127–1137 (2009)
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Because tumors can grow only to a size of 1–2 mm3
without being supplied with oxygen and nutrients by
blood vessels, the inhibition of angiogenesis has gained
clinical relevance in cancer therapy (1). The formation
of new vessels requires multiple endothelial cell division
cycles. Thus, the application of cell-cycle-inhibiting com-
pounds such as tubulin antagonists is promising in anti-
angiogenic therapy. Microtubule-inhibiting drugs turned
out to belong to the most potent antiangiogenic com-
pounds (2). Established tubulin antagonists such as pac-
litaxel or vinblastine have become part of clinical ap-
proaches for antiangiogenic standard chemotherapy.
Furthermore, promising new substances such as combret-
astatin A4 phosphate (CA4P) enter the scene, indicating
the persisting requirement for new and better com-
pounds with stronger effects and less toxicity (3–5).
Interestingly, it was found that interphase microtubules
of endothelial cells are particularly sensitive to tubulin
antagonists (6, 7). Therefore, nonmitotic effects of these
drugs seem to be very important in their antiangiogenic
action, in contrast to mitotic effects in classical cancer
therapy. Thus, the determination of the functions of
interphase microtubules in endothelial cells, especially
those involved in angiogenic processes, is essential to
conceive the mechanisms of microtubule inhibitors in
angiogenesis. Astonishingly, the characterization of the
role of interphase microtubules in angiogenesis and the
elucidation of antiangiogenic mechanisms of tubulin an-
tagonists has only just begun (8–11).
In the present study, we investigated the antiangio-
genic potential of spongistatin 1 in vitro and in vivo.
Spongistatin 1 is a macrocyclic lacton polyether,
isolated from marine sponges (12, 13). It facilitates
the disassembly of microtubules by binding to a
specific site on -tubulin, which is just overlapping
the Vinca domain (14). In the anticancer test panel of
the U.S. National Cancer Institute (NCI), spongista-
tin 1 has shown very strong effects on 20 cancer cell
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lines (15). Our own recent studies demonstrated
spongistatin 1 to be highly effective against a chemo-
therapeutic-resistant leukemia cell line without af-
fecting peripheral mononuclear blood cells, which
indicates the therapeutic aptitudes of spongistatin 1
(16). The uniqueness of its binding site on -tubulin
also gives reason to speculate that spongistatin 1 may
differ in its mode of action from other established
tubulin antagonitsts. Therefore, the investigation of
antiangiogenic properties of spongistatin 1 in com-
parison to already known drugs seemed to be most
promising.
In the present study we demonstrate strong antian-
giogenic effects of sponistatin 1 in vitro and in vivo.
These seem to be due to nonmitotic effects of
spongistatin 1 and hint toward an as yet unknown
mechanism of tubulin antagonism during angiogene-
sis: the inhibition of protein kinase C (PKC) trans-
location.
MATERIALS AND METHODS
Compounds
Spongistatin 1 and CA4P were provided by George R. Pettit
(Cancer Research Institute, Tempe, AZ, USA). Paclitaxel,
propidium iodide, and phorbol 12-myristate 13-acetate were
purchased from Sigma (Taufkirchen, Germany), vinblastine
from Hexal (Holzkirchen, Germany), nocodazole from Ap-
pliChem GmbH (Darmstadt, Germany), and staurosporine
from Cayman Chemical (Ann Arbor, MI, USA).
Cell culture and media
Primary human umbilical vein endothelial cells (HUVECs)
were isolated by collagenase treatment of umbilical cords
(17) and used at third passage. Cells were cultivated on
0.001% collagen G in endothelial growth medium (Provitro,
Berlin, Germany), containing 10% inactivated fetal calf se-
rum (FCS) and growth factors (basic fibroblast growth factor
1.0 ng/ml, Heparin 0.004 ml/ml, and epidermal growth
factor 0.1 ng/ml). M199 medium (PAN Biotech, Aidenbach,
Germany) was used as starvation medium.
Live-cell imaging
HUVECs were transfected with 7 g pEGFP-C1-tubulin
(kindly supplied by Stefan Linder, Institute for Cardiovascu-
lar Diseases, University of Munich, Munich, Germany), using
the Nucleofector II and the HUVEC Nucleofector Kit
(Amaxa, Cologne, Germany). At days 2 and 3 after transfec-
tion, cells were used for live-cell imaging (customized cell
observation chamber; Emblem, Heidelberg, Germany; and
confocal microscope (LSM 510 Meta; Zeiss, Jena, Germany).
Tubulin fractionation
HUVECs were lysed 20 min in 1,4-piperazinebis(ethane sul-
fonic acid) (PIPES) buffer [0.1 M PIPES, pH 6.9; 2.0 M
glycerol; 0.5% Triton X-100; 2 mM MgCl2; 2 mM K-EGTA salt;
5 M paclitaxel; 1 mM GTP; 1 mM PMSF; and complete®
medium (Roche, Penzberg, Germany)]. Lysates were centri-
fuged 45 min at 100,000 g, 4°C. The supernatants were
collected (fraction of soluble tubulin). The sediments were
incubated 1 h at 4°C with Ca2Cl buffer (0.1 M Tris/HCl, pH
6.8; 1 mM MgCl2; 10 mM CaCl2; 1 mM PMSF; and complete
medium). After centrifugation (10,000 g for 10 min at 4°C),
the supernatant contained the fraction of PIPES-insoluble
tubulin. Both fractions were prepared in 5 sodium dodecyl
sulfate (SDS) sample buffer [312.5 mM Tris/HCl, pH 6.8;
50% glycerol; 5% SDS; 2% dithiothreitol (DTT); 0.025%
Pyronin Y 5] for immunoblotting. The anti-tubulin antibody
(D-10) was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA), the anti--actin antibody (MAB1501R) from
Chemicon International (Hofheim, Germany).
Immunoblotting
Proteins were separated by SDS-PAGE and transferred to
polyvinylidene difluoride membranes (Immobilon-P; Milli-
pore, Eschborn, Germany) via tank blotting. Protein levels
were detected either by the ECLTM detection system (Amer-
sham Pharmacia Biotech, Little Chalfont, UK), or by the
Odyssey Infrared Imaging System version 2.1 (LI-COR Bio-
sciences, Lincoln, NE, USA).
Cell cycle analysis
Proliferating HUVECs (75,000 cells/well in a 12-well plate)
were treated for 24 h with increasing concentrations of
spongistatin 1, vinblastine, CA4P, or paclitaxel. After stimula-
tion, cell culture supernatants containing apoptotic cells were
collected. Cells were washed with PBS and harvested by
trypsine/EDTA treatment, resuspended in the cell culture
supernatant, and centrifuged at 600 g for 10 min at 4°C. After
another wash with PBS, cells were resuspended in hypotonic
fluorochrome solution (HFS) (0.1% Na3-Citrat, 0.1% Triton
X-100, and 50 g/ml propidium iodide). Cell cycle phases
were analyzed by flow cytometry on a FACSCalibur (Becton
Dickinson, Heidelberg, Germany). The intercalation of pro-
pidium iodide into DNA generates different fluorescence-
intensity peaks, depending on the DNA content of the cell.
Thus, cell cycle phases as well as apoptotic cells can be
determined (18).
Cell viability assay (relative metabolic activity)
Cell viability in HUVECs was measured by determination of
the metabolical reduction of resazurin to resorufin, using the
CellTiter-BlueTM assay (Promega, Madison, WI, USA). Here
5000 (proliferating) and 15,000 (confluent) HUVECs/well of
a 96-well plate were seeded and treated with increasing
concentrations of spongistatin 1 for 24 h. Also, 20 l of
Cell-Titer-Blue reagent was added to each well, and cells were
incubated for 4 h at 37°C. The reduction of resazurin was
determined by recording fluorescence at 560 and 590 nm in
the SpectraFluor Plus plate reader (Tecan Trading AG,
Maennedorf, Switzerland) and by calculating the ratio of
fluorescence at 560/590 nm.
Proliferation assay
The proliferation assay was performed according to the NCI
protocols for angiogenesis. Briefly, 1500 HUVECs/well were
seeded into 96-well plates. The next day, control cells were fixed
and stained with crystal violet (see below) to determine the
initial cell number. Then HUVECs were treated with increasing
concentrations of spongistatin 1, vinblastine, CA4P, or paclitaxel
for 72 h. After stimulation, cells were stained with crystal violet
solution (0.5% crystal violet in 20% methanol) for 10 min.
1128 Vol. 23 April 2009 ROTHMEIER ET AL.The FASEB Journal
Unbound crystal violet was removed by rinsing with distilled
water, and cells were subsequently air dried. Next, crystal violet,
which mainly binds to DNA, was eluted from cells with 0.1 M
sodium citrate in 50% ethanol. The absorbance of crystal violet
is proportional to the cell number and was determined with the
Sunrise ELISA reader (Tecan Trading AG) at 540 nm.
Migration scratch assay
HUVECs were seeded into 24-well plates and grown to
confluency. A wound of 1 mm was inflicted to HUVEC
monolayers by scratching them with a pipette tip. The wells
were washed with PBS to remove detached cells and incu-
bated for 16 h at 37°C in either starvation medium (no
migration), culture medium (100% migration), or culture
medium containing increasing concentrations of spongistatin
1, vinblastine, CA4P, or paclitaxel. After incubation, cells
were washed with PBS and fixed in 4% formaldehyde. One
image per well (center position) was taken on an inverted
light microscope (Axiovert 200; Zeiss, Jena, Germany) using
the Imago-QE camera system and the appending software
(Till Photonics, Graefelfing, Germany). For quantification,
these images were analyzed with the S.CORE imaging analysis
tool (S.CO LifeScience, Munich, Germany). This software
tool is able to identify the cell-covered area by using an
algorithm based on brightness and contrast values as well as
morphological information. The cell-free area correlates to
the ability of the HUVECs to migrate into the scratch.
Immunocytochemistry
HUVECs were seeded on 0.1% collagen A-coated glass cover-
slips, washed, fixed in 4% formaldehyde for 15 min, and
permeabilized with 0.2% Triton X-100 in PBS. F-actin was
stained by incubating cells for 45 min with rhodamine-
conjugated phalloidin (Invitrogen, Eugene, OR, USA) di-
luted 1:400 in PBS containing 1% BSA. Visualization and
imaging were done on a confocal microscope (LSM 510 Meta;
Zeiss).
Chemotaxis assay
Chemotaxis of spongistatin 1-treated HUVECs was investi-
gated by -slide chemotaxis (IBIDI, Martinsried, Germany).
The chemotaxis assay was performed as described in the
manual, “-Slide Chemotaxis” (http://www.ibidi.de/applica-
tions/ap_chemotaxis.html). Briefly, a HUVEC suspension
(7 l) of 5 106 cells/ml was seeded into the center chamber
of a -slide. Two opposing medium reservoirs were connected
to the seeding chamber by a thin slit. One of these reservoirs
was filled with starvation medium without FCS; the other was
filled with HUVEC culture medium containing 10% FCS,
generating by diffusion a linear and stable (48 h) FCS
gradient from 0 to 10% FCS in the seeding chamber of the
-slide. Cell movement was observed every 10 min over 24 h
by live cell imaging in a cell observation chamber (Emblem)
mounted to a confocal microscope (LSM 510 Meta; Zeiss).
Cell tracking and analysis were done using the manual
tracking plug-in (Fabrice Cordelieres, Orsay, France) and the
chemotaxis and migration tool (IBIDI) for ImageJ (U.S.
National Institutes of Health, Bethesda, MD, USA), as de-
scribed in the -slide chemotaxis protocol. The position of
cells was defined as a point at low magnification (10 lens).
Tube formation assay
MatrigelTM (BD Discovery Labware, Bedford, MA, USA) was
placed into the lower chambers of -slide angiogenesis wells
(IBIDI) and hardened for 30 min at 37°C. Then 12,000
HUVECs/well were seeded on the Matrigel and treated
overnight with 1.0 nM spongistatin 1, 5.0 nM vinblastine, 10.0
nM CA4P, or 50 nM pacliatxel. Images were taken on the
Axiovert 200 microscope (Zeiss) with the Imago-QE camera
system and the appending software (Till Photonics). The
images were analyzed with the tube formation module of
S.CORE (S.CO LifeScience). This software module identifies
cellular tubes on a multiparametric basis (depending on
brightness or contrast differences, length, and width of the
cell structure) and nodes of tubes (depending on a math-
ematic algorithm that interprets tubes and nontube cell
complexes).
Mouse aortic ring assay
Abdominal arteries of NMRI mice (Charles River Laborato-
ries, Sulzfeld, Germany) were prepared, cut in rings, and set
on Matrigel. Aortic rings were incubated for 2 days in HUVEC
culture medium before stimulation with spongistatin 1. En-
dothelial cell sprouting was documented 2 days after all
untreated rings had sprouted.
Mouse corneal micropocket assay
Male C57BL6 mice were purchased from Charles River Lab-
oratories, and micropockets were generated as described
(19). Spongistatin 1 was administered intraperitoneally at a
dose of 10 g/kg (dissolved in 2% dimethyl sulfoxide and
isotonic saline) daily for 5 days, beginning from the first
postoperative day (n5). The controls received vehicle treat-
ment only (n5). The maximal vessel length and clock hours
of circumferential neovascularization were measured on the
sixth day after corneal implantation. The length of new
vessels in the cornea was measured from the inside margin of
vessels around the limbus to the tip of the longest neovascular
sprout. The contiguous circumferential zone of neovascular-
ization was measured as clock hours (length of the limbal
vessel showing sprouts) with a 360° reticule (where 30° of arc
equals 1 clock hour, and 1 clock hour further corresponds to
1 mm limbal vessel length).
Kinome chip analysis (PepChip)
PepChip performance and analysis of the results were done as
described previously (20, 21) by Pepscan Presto BV (Lelystad,
The Netherlands; for detailed protocol see http://www.
pepscanpresto.com/files/PepChip%20Kinase%20Lysate%
20Protocol_v5.pdf). On PepChip, 1152 different peptides
with specific phosphorylation motifs for upstream kinases
were spotted in triplicates. Confluent HUVECs in 100 mm
dishes were treated for 30 min with spongistatin 1 (5.0 nM),
vinblastine (10 nM), or CA4P (20 nM). Native protein lysates
of these cells were generated by lysing cells with M-PER
Mammalian Protein Extraction Reagent (Pierce, Rockford,
IL, USA), containing 2.5 mM Na4-pyrophosphate, 2 mM
Na2--glycerophosphate, 1 mM Na3VO4, and 1 mM NaF.
Lysates were centrifuged 10 min at 13,000 rpm, 4°C, and
supernatants were frozen immediately in liquid nitrogen.
Here 70 l lysates/array was mixed with 10 l activation
solution (20 Ci -33ATP, 50% glycerol, 5 mM DTT, 50 mM
MgCl2, 50 mM MnCl2, 250 g/ml PEG 8000, and 250 g/ml
BSA) and centrifuged 5 min at 14,000 g. Next, 70 l of the
supernatant was loaded onto the array and incubated for 2 h
at 37°C in saturated humidity. Chips were washed in 2 cycles,
first 5 min in 2 M NaCl containing 1% Triton X-100, followed
by 5 min in PBS containing 1% Triton X-100. Afterward, chips
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were rinsed 3 times with distilled water and then air-dried.
Phosphor-storage screens were exposed to the chip for 24 h to
determine and to quantify the phosphorylation status of
peptides (i.e., kinase substrates), which gave information
about the activity of the associated upstream kinase. The
phosphorylation status of the chips with untreated or treated
cells (spongistatin 1, vinblastine, or CA4P) was compared spot
by spot. The results were ranked by extent of inhibition of
phosphorylation. The kinases inhibited most according to
this score are shown in Table 1 for each tubulin antagonist
tested.
PKC activity: (ser)-substrate phosphorylation
HUVECs were treated with 5.0 nM spongistatin 1 for 30 min,
lysed in radioimmunoprecipitation assay buffer (150 mM
NaCl, 50 mM Tris/HCl, 1% Nonidet-P40, 0.25% Deoxycholat,
0.1% SDS, 1 mM PMSF, 1 mM NaF, 1 mM Na3VO4, and
complete medium), and centrifuged at 10,000 g, 10 min, 4°C.
The supernatants were prepared in 5 SDS sample buffer for
immunoblotting. Phospho-(Ser) PKC substrate antibody was
purchased from Cell Signaling Technology (CST, Frankfurt,
Germany).
PKC in vitro activity assay
Potential direct inhibition of PKC isozymes in vitro by
spongistatin 1 was assessed using a micellar-based assay. Here,
150 ng of recombinant glutathione S-transferase-tagged PKC
isozyme , I, II, 	, ε, or 
 (kindly provided by Dr. M.
Kubbutat, ProQinase Ltd., Freiburg, Germany) was incubated
in a buffer containing 20 mM Tris-HCl, pH 7.5, and 20 mM
MgCl2, with 50 M PKC--19–31/Ser-25 substrate peptide
(NeoMPS, Strasbourg, France), 1 mM CaCl2, 10 M phospha-
tidylserine (Sigma), 1 M 12-O-tetradecanoylphorbol-13-ace-
tate (Sigma), 40 M ATP, and 1 Ci -33ATP (PerkinElmer,
Fremont, CA, USA; 3000 Ci/mM) per 100 l as described
previously (22). In the assays for PKC	 and ε CaCl2, and for
PKC
 CaCl2, phosphatidylserine and 12-O-tetradecanoylphor-
bol-13-acetate were omitted. Samples containing 100 nM of
spongistatin 1 were compared to controls. The samples were
incubated for 10 min at 30°C and subsequently loaded onto
phosphocellulose filter disks (Whatman, Dassel, Germany).
The membranes were washed 3 times with 1.5% phosphoric
acid and twice with distilled water. Then 2 ml of scintillation
fluid (Ultima Gold; PerkinElmer) was added to each filter
disk, and radioactivity was counted with a liquid scintillation
counter.
PKC translocation
HUVEC lysates were separated into a cytosolic and a mem-
branous fraction, as described previously by Li et al. (23).
Briefly, HUVECs were preincubated with either 5.0 nM
spongistatin 1 or 10.0 M nocodazole before stimulation with
10 nM phorbol 12-myristate 13-acetate (PMA) or stimulated
with 10 nM PMA alone, washed twice with ice-cold PBS, and
homogenized in lysing buffer (50 mM Tris/HCl, pH 7.5; 0.5
mM EDTA; 0.5 mm EGTA; 2.0 mM DTT; 7.0 mM glutathione;
10% glycerol; 1.0 mm PMSF; and complete medium). Lysates
were centrifuged at 100,000 g for 1 h. The supernatant
(cytosolic fraction) was collected. The sediment was washed
in lysing buffer containing 1.0 M NaCl and centrifuged at
100,000 g for 30 min. The supernatant was discarded, and the
pellet was solubilized with lysing buffer containing 20 mM
3-[(3-cholamidopropyl) diethylammonio]-1 propane sulfo-
nate at 4°C for 30 min. After centrifugation at 100,000 g for
1 h, the supernatant was kept as membranous fraction. Both
fractions were used for Western blotting. Antibodies against
PKC, PKC	, and PKCε were purchased from Santa-Cruz, the
anti-VE-Cadherin antibody from Cell Signaling Technology.
Statistical analysis
Data were expressed as means  se, and analyzed using 1-way
ANOVA, Student’s t test, or rank-sum test. Values of P  0.05
were considered statistically significant.
RESULTS
Spongistatin 1 causes disassembly of microtubules
in HUVECs
To test whether spongistatin 1 causes microtubule
disassembly in endothelial cells, 2 different ap-
proaches were pursued. First, live cell imaging of
green fluorescent protein (GFP)-tubulin-transfected
HUVECs, treated with 2.0 nM spongistatin 1 for 16 h,
was performed. At the beginning of the record, a
clearly structured microtubule skeleton could be
TABLE 1. Kinome array data showing kinases that were reduced most in their activity in tubulin-antagonist-treated HUVECs compared
to control cells
Spongistatin 1 Vinblastine CA4P
Peptide Kinase R.A. Peptide Kinase R.A. Peptide Kinase R.A.
RSKKNSLALSL PAK1 0.6 RKKKVSSTKRH PKC 0.4 DNSSDSDYDLH LCK, FYN 0.7
LLEDDSDEEED PKC 0.6 SWKENSPLNVS PKC 0.4 LCQAFSDVILA PLK1 0.6
KRRGASDLSSE CK2 0.5 RDKEVSDDEAE CK2 0.4 LERGNSGLGFS CaMKII 0.6
RKMKDTDSEEE c-SRC 0.4 NIIHGSDSVES NDK A 0.3 NYIPETPPPGY ERK 0.6
GLRRSSKFCLK EGFR 0.3 YFRYLSEVASG PKC
 0.3 KERRRTESINS CK2 0.5
PTQPTSASPSL CK2 0.1 GGARASPATQP ERK 0.3 RKKKVSSTKRH RSK, PKA 0.5
LCQAFSDVILA AKT1 0 DEYNVTPSPPG GSK3 0.3 GFFSSSESGAP PKC 0.5
ERGQEYLILEK TEC kinase 0.3 LEPLCTPVVTC PKC 0.5
TDNEDYEHDDE SYK 0.3 PEPGPYAQPSV EGFR 0.4
QGISFSQPTCP ATR 0 KKKKGSLDSDN PKA 0.3
Some kinases are represented by multiple substrate peptides. R.A.  residual activity.
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detected in the cells. With prolonged incubation with
spongistatin 1, tubulin fibers disassembled and left a
diffuse GFP signal distributed over the whole cell
(Fig. 1A; Supplemental Movie 1). Second, HUVECs
treated with 1.0 M paclitaxel or 0.1–2.0 nM spongista-
tin 1 for 4 h were fractionated into a PIPES buffer-
soluble fraction, containing tubulin heterodimers, and
a PIPES buffer-insoluble fraction, containing polymer-
ized microtubules. As was to be expected, the microtu-
bule-stabilizing compound paclitaxel caused an in-
crease of tubulin in the fraction of polymerized
microtubules. In contrast, the incubation with
spongistatin 1 results in dose-dependent decrease of
tubulin in this fraction as a result of microtubule
disassembly (Fig. 1B).
Spongistatin 1 is antiproliferative at
a nontoxic concentration
Antiproliferative effects of spongistatin 1 on endothe-
lial cells were investigated in a cell viability assay,
DNA-fragmentation analysis, proliferation assay, and
cell cycle analysis. Acute cytotoxicity of spongistatin 1
on proliferating cells was observed at a concentration as
low as 5.0 nM, as judged by the significant decrease in
the metabolic activity of spongistatin 1-treated cells. In
contrast, cytotoxic effects of spongistatin 1 on conflu-
ent HUVECs occurred at a concentration as high as
50.0 nM (Fig. 2A). At concentrations of 500 pM and 1.0
nM, spongistatin 1 induced a slight increase, up to 5%
apoptotic cells. At a concentration of 2.0 nM spongista-
tin 1, up to 20% of the cells were apoptotic. In
comparison to the established tubulin antagonists vin-
blastine, CA4P, and paclcitaxel, spongistatin 1 induced
apoptosis most efficiently (Fig. 2B). Astonishingly, pro-
liferation of HUVECs was already inhibited at a con-
centration as low as 100 pM spongistatin 1, whereas
more than 25–500 higher concentrations of vinblas-
tine (2.5 nM), C4AP (7.5 nM), or paclitaxel (50.0 nM),
respectively, were needed to inhibit endothelial prolif-
eration to a similar degree (Fig. 2C). Tubulin antago-
nists disrupt the mitotic spindle of dividing cells, cause
cell cycle arrest in the transition from G2 to M phase,
and consequently inhibit proliferation. As expected,
spongistatin 1 also caused G2/M arrest, again at lower
concentrations than vinblastine, CA4P, and paclitaxel.
However, significant inhibition of cell cycle progression
occurred starting at a concentration of 1.0 nM
spongistatin 1, a 10 higher concentration than that
needed to inhibit proliferation (Fig. 2D).
Spongistatin 1 inhibits migration of endothelial cells
and influences F-actin organization
Migration is a crucial step in angiogenesis. Therefore,
the influence of spongistatin 1 on endothelial cell
migration was investigated in a scratch assay. Spongista-
tin 1 effectively inhibited wound closure in a dose-
dependent manner, with an IC50 of 1.0 nM, and was
therewith again more potent than the established tu-
bulin antagonists vinblastine (7.5 nM), C4AP (10.0
nM), or paclitaxel (25.0 nM) (Fig. 3A, B).
Actin and its motor proteins are supposed to gener-
ate the main force driving cells forward. Hence, alter-
ations in F-actin organization could be expected in cells
that are inhibited in migration. Growth-factor-deprived
cells (starvation medium) do not migrate. In these
cells, actin is organized in cortical rings, and lamellopo-
dia only barely exist (Fig. 3C, left panel). In migrating
HUVECs (culture medium), F-actin is arranged in
stress fibers within the cell body and lamellopodia at
the leading edge. Both were directed toward the wound
(Fig. 3C, middle panel). Spongistatin 1-treated cells
exhibited the combined characteristics of F-actin ar-
rangement in both migrating and nonmigrating cells.
Both actin fibers in the cell body and cortical rings were
formed. Furthermore, the appearance of lamellopodia
was reduced on spongistatin 1 treatment (Fig. 3C, right
panel).
Spongistatin 1 reduces chemotaxis,
but not chemokinesis
The influence of spongistatin 1 on directed migration
of endothelial cells was investigated in a chemotaxis
Figure 1. Live-cell imaging and tubulin fractionation proved the disassembly of microtubules by spongistatin 1.
A) GFP-tubulin-transfected HUVECs were stimulated with 2.0 nM spongistatin 1 for 16 h. Bottom panels show magnification of
microtubules of the HUVECs. B) Cell lysates of paclitaxel (pacl)- and spongistatin 1 (SP1)-stimulated HUVECs were separated
in PIPES buffer-soluble and -insoluble fractions. Tubulin heterodimers were detected in the soluble fraction, polymerized
microtubules in the insoluble fraction.
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assay. In this assay, HUVECs were exposed to a serum
gradient ranging from 0 to 10% FCS. Untreated
HUVECs were attracted by FCS and moved along the
serum gradient in the direction of the reservoir filled
with FCS-containing medium. Their directionality to
the serum was expressed in y values, because the
gradient runs along the y axis of the cell tracking plot
(Fig. 4A). The values of control (untreated) HUVECs
were set as 1.0. Thus, in control HUVECs, the migration
index of each single cell in FCS gradient (y-forward) was
1.00 0.264. In contrast, spongistatin 1-treated cells were
reduced in their directionality for FCS, which is reflected
in their value for y-forward (0.0490.087).
Besides the attraction toward FCS, single parameters
of chemotactic migration were evaluated. The euclid-
ean distance is the direct distance between starting
point and end point of a cell track and was reduced to
half (0.5480.024) by treatment with 1.0 nM spongista-
tin 1. Astonishingly, accumulative distance was not
reduced on treatment with spongistatin 1, indicating
Figure 2. Spongistatin 1 exerts strong antiproliferative effects on HUVECs in
nontoxic concentrations. A) Cytotoxic concentrations of spongistatin 1 were
determined by metabolic conversion of resazurin to resorufin in confluent and
proliferative HUVECs. Significantly reduced metabolic activity could be ob-
served at a concentration of spongistatin 1 as low as 5.0 nM in proliferative cells,
whereas in confluent HUVECs, a significant reduction could be determined at
50.0 nM of spongistatin 1. B–D) Effects of spongistatin 1 on apoptosis(B),
proliferation (C), and cell cycle (D) were analyzed in proliferating HUVECs in
comparison with established tubulin antagonists vinblastine, CA4P, and pacli-
taxel. *P  0.05; 1-way ANOVA.
Figure 3. Spongistatin 1 inhibits migration of HUVECs. A) Spongistatin 1, vinblastine, CA4P, and paclitaxel inhibited wound
closure of a scratched HUVEC monolayer in a dose-dependent manner. *P  0.05; 1-way ANOVA. B) Representative images of
quantification of wound healing. Cell-free area is gray. C) Actin cytoskeleton in migrating HUVECs: under spongistatin 1
treament, formation of lammelipodia is reduced, and formation of cortical rings is increased.
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that spongistatin 1 does not disrupt cellular movement
itself (chemokinesis) but the ability of HUVECs for
directional migration (Fig. 4B).
Tube formation and endothelial sprouting of aortic
rings are inhibited by spongistatin 1
The inhibition of endothelial tube formation on Matri-
gel is a characteristic attribute of antiangiogenic agents.
In time-lapse microscopy, freshly seeded HUVECs formed
a tubular network on Matrigel within only 4–7 h
(Supplemental Movies 2 and 3). However, when seed-
ing medium contained spongistatin 1 (1.0 nM), vinblas-
tine (5.0 nM), CA4P (10.0 nM), or paclitaxel (50.0
nM), tube formation was reduced to half, as judged by
the length of the tubes and the number of nodes
(Fig. 5A, B).
In the ex vivo mouse aortic ring model, slices of
mouse aortas were incubated on Matrigel. Without
spongistatin 1 treatment (control), endothelial cells
sprouted within 3–5 days. Treatment of the aortic rings
with 0.5 nM spongistatin 1 yielded reduced sprout
formation, which was completely suppressed by treat-
ment with 1.0 nM spongistatin 1 (Fig. 5C).
Spongistatin 1 suppresses neovascularization of the
mouse cornea
Antiangiogenic properties of spongistatin 1 in vivo were
determined in the mouse corneal micropocket assay.
Spongistatin 1 was administered i.p. to investigate its
impact on neovascularization of the cornea after 5 days
of stimulation with bFGF.
Pellets applied to corneas containing sucrose alumi-
num sulfate alone without bFGF (sham treatment) did
not induce corneal neovascularization (data not shown).
Corneal neovascularization induced by bFGF-containing
pellets in spongistatin 1-treated animals was markedly
reduced compared to control animals (Fig. 6A). Quanti-
tative comparison showed that important parameters
for measuring the extent of corneal neovascularization
were significantly lower in spongistatin 1-treated ani-
mals: that is, the circumference of neovascularization
and the vessel length in the corneas were reduced by 37
and 53%, respectively, in spongistatin 1-treated mice
compared to corneas from untreated control animals
(Fig. 6B, C).
Kinome array reveals common features and
differences of the activity profile
of tubulin antagonists
To investigate which signaling pathways are particularly
affected by spongistatin 1 or the other microtubule-
disrupting drugs, a kinome array (PepChip) was per-
formed. The kinases with the highest reduction of
activity in treated cells compared to control cells are
displayed in Table 1. The kinase inhibition profile of
the microtubule inhibitors is different from each other.
Interestingly, in all 3 treatment groups the activity of
PKC was reduced. The importance of PKC isoforms in
angiogenesis, especially of PKC, 	, and ε, has been
described previously (24–26). Therefore, the activity of
PKC isoforms in HUVECs treated with spongistatin 1
was investigated in more detail.
Spongistatin 1 inhibits phosphorylation of specific
PKC serine substrates, but does not inhibit PKC
activity directly
To validate the PepChip data of reduced PKC activity,
Western blot analysis of phosphorylated serine residues
of PKC substrates was performed. The well-established
kinase inhibitor staurosporine, which is known to in-
hibit PKC activity by binding the ATP-site, caused
complete inhibition of PKC serine-substrate phosphor-
ylation, whereas spongistatin 1 reduced phosphoryla-
tion of not all but of distinct serine substrates (arrows in
Fig. 7A). This suggests that spongistatin 1 does not
Figure 4. Spongistatin 1 reduces directional migration in HUVECs.
A) Track plots of control cells and spongistatin 1-treated cells of represen-
tative chemotaxis experiments. Starting point of each single cell is placed
in the center of the diagram. Tracks of cells moving toward FCS are black;
tracks of cells without attraction to FCS are gray. B) Diagram shows analysis of y-forward (y-forward migration index of
each cell), euclidean distance (direct distance between starting point and end point), and accumulated distance. Means
of control cells were set as 1.0. Data are means  se. *P  0.05; Student’s t test.
1133THE TUBULIN ANTAGONIST SPONGISTATIN INHIBITS PKC
inhibit total PKC activity, but perhaps the activity of a
specific PKC isoform.
A PKC in vitro activity assay was performed with
spongistatin 1 to investigate whether a specific PKC
isoform is directly inhibited by this compound. Even at
a much higher concentration than needed for its
antiangiogenic effect (100.0 nM), spongistatin 1 did
not reduce the activity of any of the tested PKC isoforms
, I, II, 	, ε, or 
 (Fig. 7B).
Spongistatin 1 inhibits the translocation of PKC to
the membrane
Because most of the PKC isoforms have to be translo-
cated from the cytoplasm to membranes to become
activated and translocation processes can depend on
microtubules, the tubulin antagonist spongistatin 1 may
influence the activity of specific PKC isoforms via
inhibition of their transport to membranes. PKC trans-
location was induced with 10 nM PMA for 2 h. Prein-
cubation with spongistatin 1 prior to PMA-stimulation
resulted in reduced transport of PKC to membranes.
Accordingly, an enrichment of PKC in the cytoplasm was
observed. Interestingly, the translocation of PKC	 and ε,
which are also supposed to be involved in angiogenesis,
was not affected by spongistatin 1 (Fig. 8A). Quantitative
analysis of Western blots of PKC isoforms after mem-
brane/cytosol fractionation demonstrated the statisti-
cal significance of reduced PKC translocation. To
investigate whether the translocation of PKC is a
microtubule-dependent process and spongistatin 1 in-
hibits the translocation of PKC by disrupting microtu-
bules, translocation studies were also performed with
the well-established and structurally unrelated microtu-
bules-disrupting agent nocodazole (10 M before stim-
ulation with PMA). Pretreatment with nocodazole also
reduced PMA-stimulated translocation of PKC to the
membrane (Fig. 8B).
DISCUSSION
In addition to classical cytostatic chemotherapy, antian-
giogenic therapy has become a very important ap-
proach in cancer treatment. Meeting the increasing
demand for new appropriate drugs for antiangiogenic
therapy, this study presents the marine compound
spongistatin 1 to be a strong antiangiogenic agent both
in vitro and in vivo. Furthermore, investigations of
spongistatin 1 included the comparison with other
Figure 5. Tube formation and endothelial sprouting are inhibited by spongistatin 1. A) Representative images of tube formation.
S.CORE tube formation analysis determines cellular structures as tubes (dark gray) and nodes (light gray). B) Tube formation
of endothelial cells on Matrigel was reduced to half by 1.0 nM spongistatin 1 (SP1), 5.0 nM vinblastine (vinb), 10.0 nM CA4P,
and 50.0 nM paclitaxel (pacl). *P  0.05; 1-way ANOVA. C) Representative pictures of aortic ring assay showing vascular
sprouting of the 3 treatment groups (control and 0.5 and 1.0 nM spongistatin 1).
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microtubule-depolymerizing compounds, vinblastine,
and CA4P. All 3 compounds bind to different sites on
-tubulin. Thus, the comparison allows distinguishing
between compound-specific effects and effects that
depend on disruption of the microtubules per se.
In comparison to the other tested tubulin antago-
nists, spongistatin 1 is pharmacologically the most
potent compound. A closer inspection of the microtu-
bule-depolymerizing compounds in the different func-
tional assays reveals that effects on endothelial migra-
tion, tube formation, G2/M arrest, and induction of
apoptosis occur at about the same inhibitory concen-
tration of the respective compound. Therefore, effects
of spongistatin 1, vinblastine, and CA4P in the men-
tioned assays can probably be ascribed to a common
mode of action, the depolymerization of the microtu-
bules. Astonishingly, spongistatin 1 exerts effects on
endothelial proliferation at a concentration (100 pM)
at which neither cell cycle was affected, nor apoptosis
or cytotoxicity were induced. This phenomenon was
not observed in vinblastine- or CA4P-treated cells.
Therefore, antiproliferative effects of spongistatin 1
might be related to individual properties of the com-
pound and have to be distinguished from the direct
microtubule-inhibiting action.
Main processes of angiogenesis, which presumably
require the functionality of interphase microtubules,
are cellular motility and cellular signaling. In most cell
types, including endothelial cells, the breakdown of the
microtubules correlates with motility impairments. Mi-
crotubules may be involved directly in the generation of
protrusive force, since plus-ends of growing microtu-
bules generate a force of several pN, which is enough to
deform lipid bilayers (27). However, the present study
demonstrates that spongistatin 1 does not act on migra-
tion by inhibition of traction forces. Rather, directionality,
not cellular motility itself, was affected by spongistatin 1 in
the chemotaxis assay.
In amoeba and fibroblasts microtubules are essential
for the generation and maintenance of cellular polarity
Figure 7. Spongistatin 1 inhibits phosphorylation of PKC
substrates and translocation of PKC without directly block-
ing PKC activity. A) Western blot analysis to investigate
phosphorylation activity of PKC in spongistatin 1-treated cells
(same stimulation as in PepChip), using an antibody against
phosphorylated PKC substrates (serine residues). Kinase in-
hibitor staurosporine (stauro) abolished phosphorylation of
PKC substrates. In contrast, spongistatin 1 reduced phosphor-
ylation only of distinct PKC substrates (arrows). B) In PKC
in vitro assay, spongistatin 1 did not significantly inhibit
phosphorylation activity of PKC isoforms , I, II, 	, ε, or 

(P0.05; rank-sum test).
Figure 6. Spongistatin 1 inhibits neovascularization of mouse
corneas. A) Corneal neovascularization was examined and
photographed on day 6 after implantation of pellets contain-
ing bFGF (20 view of mouse eye; dots encircle area of
implanted pellet). Corneal neovascularization in spongistatin
1-treated animals was markedly reduced compared to vehicle-
treated control animals (control). B, C) Angiogenic responses
were measured as clock hours (B) and vessel length of
neovascularization (C). *P  0.001; Student’s t test.
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(28–30). Disassembly of microtubules in these cells
causes the loss of polarization and the ability of direc-
tional migration. Consistently, the depolymerization of
microtubules by spongistatin 1 might abrogate polar-
ization in the endothelial cell and consequently reduce
directed migration. The disarrangement of actin in
migrating cells treated with spongistatin 1 might be a
symptom of this loss of polarization.
Signaling processes that are involved in polarization
and the whole process of angiogenesis often depend on
intracellular translocation of signaling molecules. Micro-
tubules are known to facilitate such translocations, but
because signaling pathways vary in different cell types and
translocation processes also occur along actin filaments,
the impact of functional microtubules on endothelial
signaling is not very well characterized. To identify micro-
tubule-dependent signaling pathways involved in the ini-
tiation phase of angiogenesis and that might be affected
by tubulin antagonism, a kinome array (PepChip) with
spongistatin 1-, vinblastine-, or CA4P-treated HUVECs was
performed. This array has shown a common subset of
kinases that were inhibited by all 3 tubulin antagonists.
The respective kinases, mostly isoforms of PKC, and the
signaling pathway in which they are involved seem to
depend on functional interphase microtubules.
Continuing investigations have shown that spongista-
tin 1 does not affect PKC activity by direct inhibition.
Rather, the translocation of PKC from the cytosol to
the membrane and its activation related to this translo-
cation are inhibited by spongistatin 1. In fact, the
translocation of PKC seems to be microtubule depen-
dent, because preincubation with nocodazole, a struc-
turally nonrelated tubulin antagonist, also reduced
PMA-induced translocation of PKC to the membrane.
In line with this, PKC translocation has been shown to
be microtubule dependent in neurons and smooth
muscle cells (31, 32). However, this is the first time that
microtubule-dependent PKC translocation is shown in
endothelial cells.
Previous work on knockdown and overexpression of
PKC in endothelial cells has clearly demonstrated that
PKC is essential for angiogenesis: migration and cord
formation are inhibited by PKC knockdown, whereas
PKC overexpression results in increased proliferation,
migration, and tube formation (33–35). Antisense RNA
studies on PKC revealed that endothelial cells are not
able to adhere to an extracellular matrix without func-
tional PKC (34). Further, it is known that VEGF-induced
proliferation requires PKC (35), and it has been shown
that PMA-induced angiogenesis depends on PKC activity
(36). Hence, inhibition of interphase microtubules by
tubulin antagonists and subsequently reduced PKC
translocation might provide a new mechanism by which
tubulin antagonists act on angiogenesis.
The kinase inhibition profile of the different tubulin
antagonists exhibits common features as well as differ-
ences between the single compounds, indicating that
effects of microtubule-inhibiting drugs could be com-
pound specific. These specificities might depend on the
binding site on -tubulin and associated competition with
other microtubule-binding proteins. Furthermore, the
respective compound might inhibit targets aside from
-tubulin. These differences in the action of tubulin
antagonists could be relevant for therapeutic consider-
ations and might help to overcome chemoresistance.
In summary, elaborating the antiangiogenic profile
of spongistatin 1 has demonstrated the impressive
potency of this compound. Moreover, investigation of
the underlying mechanisms has shown that spongista-
tin 1 inhibits directional migration but not chemokine-
sis and the translocation of PKC to the membrane.
These effects could represent a prototypic pathway of
Figure 8. Spongistatin 1 and nocodazole disrupt translocation of PKC. A) Detection of the PKCisoforms , 	, and ε in
membranous and cytoplasmic fractions of HUVECs that were either stimulated with 10 nM PMA for 2 h (PMA), or preincubated
with 5 nM spongistatin 1 before PMA-stimulus (SP1). Detection of VE-cadherin (VEC) and -actin demonstrated purity of the
fractions and equal protein loading. B) To investigate whether inhibition of translocation of PKC is a microtubule-dependent
effect, experiment was repeated with established microtubule-disrupting agent nocodazole (preincubation with 10 M before
PMA stimulus). *P  0.05 vs. PMA; rank-sum test.
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the still poorly understood antiangiogenic action of
tubulin antagonists.
This work has been partially supported by the European
Community (FP6-2002-Life Science & Health, Prokinase Re-
search Project, project no. LSHB-CT-2004-503467).
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